Intuitive Surgical, Inc. (NASDAQ:ISRG) Given Average Rating of "Moderate Buy" by Analysts

Intuitive Surgical, Inc. (NASDAQ:ISRG - Get Free Report) has received a consensus rating of "Moderate Buy" from the seventeen analysts that are currently covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $396.17.

Several research firms recently weighed in on ISRG. StockNews.com cut shares of Intuitive Surgical from a "buy" rating to a "hold" rating in a research note on Thursday, February 29th. Royal Bank of Canada raised their price target on Intuitive Surgical from $400.00 to $432.00 and gave the company an "outperform" rating in a report on Wednesday, January 24th. Robert W. Baird cut their price target on Intuitive Surgical from $440.00 to $436.00 and set an "outperform" rating for the company in a report on Friday, April 19th. BTIG Research raised their price target on Intuitive Surgical from $412.00 to $421.00 and gave the company a "buy" rating in a report on Friday, April 19th. Finally, Stifel Nicolaus raised their price target on Intuitive Surgical from $420.00 to $430.00 and gave the company a "buy" rating in a report on Monday, April 8th.

Intuitive Surgical Stock Down 0.3 %

Shares of NASDAQ:ISRG traded down $1.21 during midday trading on Wednesday, hitting $400.90. The stock had a trading volume of 1,355,261 shares, compared to its average volume of 1,544,957. Intuitive Surgical has a 12 month low of $254.85 and a 12 month high of $408.43. The business's 50-day simple moving average is $386.00 and its 200-day simple moving average is $360.92. The company has a market cap of $142.20 billion, a P/E ratio of 72.36, a PEG ratio of 5.17 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business had revenue of $1.89 billion during the quarter, compared to analysts' expectations of $1.87 billion. During the same period last year, the business earned $1.00 earnings per share. The firm's revenue was up 11.5% on a year-over-year basis. As a group, equities analysts predict that Intuitive Surgical will post 4.8 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Marshall Mohr sold 108,790 shares of the firm's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares in the company, valued at $10,349,795.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP Marshall Mohr sold 108,790 shares of the firm's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares in the company, valued at $10,349,795.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mark Brosius sold 175 shares of the firm's stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $387.22, for a total value of $67,763.50. Following the completion of the transaction, the senior vice president now owns 533 shares in the company, valued at approximately $206,388.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 148,290 shares of company stock worth $57,207,154. Company insiders own 0.80% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ISRG. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in Intuitive Surgical by 7.3% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 736 shares of the medical equipment provider's stock valued at $215,000 after acquiring an additional 50 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd grew its position in Intuitive Surgical by 55.3% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,126 shares of the medical equipment provider's stock valued at $329,000 after acquiring an additional 401 shares during the last quarter. Berger Financial Group Inc grew its position in Intuitive Surgical by 25.9% in the third quarter. Berger Financial Group Inc now owns 6,086 shares of the medical equipment provider's stock valued at $1,779,000 after acquiring an additional 1,252 shares during the last quarter. US Bancorp DE grew its holdings in shares of Intuitive Surgical by 0.3% during the third quarter. US Bancorp DE now owns 62,039 shares of the medical equipment provider's stock worth $18,133,000 after purchasing an additional 186 shares during the last quarter. Finally, Certuity LLC grew its holdings in shares of Intuitive Surgical by 7.1% during the third quarter. Certuity LLC now owns 1,947 shares of the medical equipment provider's stock worth $569,000 after purchasing an additional 129 shares during the last quarter. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.